In the base-case, the use of hip protectors was dominant so no incremental cost-effectiveness ratio was calculated. The use of hip protectors ceased to be cost-saving when their use cost $397 per 18 months or more.
At the maximum estimated cost of $695 per person, the incremental cost-effectiveness was $30,600/QALY.
The one-way sensitivity analysis across all the ranges of cost revealed the hip protector strategy was dominant, except for the cost of the hip protectors.
The two-way sensitivity analysis on hospital costs (per person) and hip protector costs (per person) indicated that the hip protectors strategy was cost-saving or cost-neutral if it cost less than or equal to $175 over 18 months.
If the hospitalisation cost at least $10,000, the break-even point under which hip protectors were cost-saving was $290.